These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32913556)

  • 21. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF alterations are associated with complex mutational profiles in malignant melanoma.
    Daniotti M; Oggionni M; Ranzani T; Vallacchi V; Campi V; Di Stasi D; Torre GD; Perrone F; Luoni C; Suardi S; Frattini M; Pilotti S; Anichini A; Tragni G; Parmiani G; Pierotti MA; Rodolfo M
    Oncogene; 2004 Aug; 23(35):5968-77. PubMed ID: 15195137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells.
    Stejerean-Todoran I; Gimotty PA; Watters A; Brafford P; Krepler C; Godok T; Li H; Bonilla Del Rio Z; Zieseniss A; Katschinski DM; Sertel SM; Rizzoli SO; Garman B; Nathanson KL; Xu X; Chen Q; Oswald JH; Lotem M; Mills GB; Davies MA; Schön MP; Bogeski I; Herlyn M; Vultur A
    Neuro Oncol; 2023 Apr; 25(4):674-686. PubMed ID: 36054930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review.
    Tan XL; Le A; Tang H; Brown M; Scherrer E; Han J; Jiang R; Diede SJ; Shui IM
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
    Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy.
    Hicks WH; Gattie LC; Traylor JI; Davar D; Najjar YG; Richardson DO TE; McBrayer SK; Abdullah KG
    bioRxiv; 2024 Jan; ():. PubMed ID: 38328251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Era in the Management of Melanoma Brain Metastases.
    Tawbi HA; Boutros C; Kok D; Robert C; McArthur G
    Am Soc Clin Oncol Educ Book; 2018 May; 38():741-750. PubMed ID: 30231345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
    Iida Y; Salomon MP; Hata K; Tran K; Ohe S; Griffiths CF; Hsu SC; Nelson N; Hoon DSB
    BMC Cancer; 2018 Oct; 18(1):1054. PubMed ID: 30373548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
    Sperduto PW; Jiang W; Brown PD; Braunstein S; Sneed P; Wattson DA; Shih HA; Bangdiwala A; Shanley R; Lockney NA; Beal K; Lou E; Amatruda T; Sperduto WA; Kirkpatrick JP; Yeh N; Gaspar LE; Molitoris JK; Masucci L; Roberge D; Yu J; Chiang V; Mehta M
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1069-1077. PubMed ID: 28721890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
    Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
    Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
    Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas.
    Lee JJ; Sholl LM; Lindeman NI; Granter SR; Laga AC; Shivdasani P; Chin G; Luke JJ; Ott PA; Hodi FS; Mihm MC; Lin JY; Werchniak AE; Haynes HA; Bailey N; Liu R; Murphy GF; Lian CG
    Clin Epigenetics; 2015; 7(1):59. PubMed ID: 26221190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
    Johnson DB; Frampton GM; Rioth MJ; Yusko E; Xu Y; Guo X; Ennis RC; Fabrizio D; Chalmers ZR; Greenbowe J; Ali SM; Balasubramanian S; Sun JX; He Y; Frederick DT; Puzanov I; Balko JM; Cates JM; Ross JS; Sanders C; Robins H; Shyr Y; Miller VA; Stephens PJ; Sullivan RJ; Sosman JA; Lovly CM
    Cancer Immunol Res; 2016 Nov; 4(11):959-967. PubMed ID: 27671167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
    Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
    Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitivity of different MRI sequences in the early detection of melanoma brain metastases.
    Deike-Hofmann K; Thünemann D; Breckwoldt MO; Schwarz D; Radbruch A; Enk A; Bendszus M; Hassel J; Schlemmer HP; Bäumer P
    PLoS One; 2018; 13(3):e0193946. PubMed ID: 29596475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
    Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
    Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.